Nabriva Therapeutics (NASDAQ:NBRV) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV) in a report issued on Wednesday. The firm issued a hold rating on the biotechnology company’s stock.

Nabriva Therapeutics Stock Performance

The company has a quick ratio of 0.52, a current ratio of 0.85 and a debt-to-equity ratio of 0.12. Nabriva Therapeutics has a 1-year low of $1.22 and a 1-year high of $8.45. The company has a 50 day simple moving average of $0.14 and a 200-day simple moving average of $0.61. The stock has a market capitalization of $45.46 million, a PE ratio of -0.07 and a beta of 1.53.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC increased its stake in shares of Nabriva Therapeutics plc (NASDAQ:NBRV) by 102.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 795,938 shares of the biotechnology company’s stock after purchasing an additional 402,144 shares during the quarter. Renaissance Technologies LLC owned 0.13% of Nabriva Therapeutics worth $145,000 as of its most recent SEC filing. Institutional investors own 0.27% of the company’s stock.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.